Latest news and press releases about BioCryst Pharmaceuticals, Inc. (BCRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema.
Price
| Price | $8.43 |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -4.79 |
| EV / EBITDA | -7.75 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 101.55% |
| Return on Invested Capital | -88.96% |
| Return on Assets | -68.96% |
| Gross Margin | 23.52% |
| Operating Margin | -33.29% |
| Net Margin | -40.90% |
Related companies: ARDX · MAZE · NTLA · PHVS · STOK · SYRE · TRVI
Explore sector: Healthcare · Biotechnology
More sections of BCRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks